NCT03070301View on ClinicalTrials.gov

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 27, 2017

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions
Neuroendocrine Tumors
Interventions
DRUG

LEE011

LEE011 200 mg daily

DRUG

everolimus

everolimus 5 mg daily or 2.5mg daily

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

77030

Md Anderson Cancer Center, Houston

02114

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

M.D. Anderson Cancer Center

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER